Larimar Therapeutics, INC 8-K filings

Larimar Therapeutics reported strong Q2 2026 results, highlighting progress in its rolling BLA submission for nomlabofusp and positive long-term study data for Friedreich's Ataxia.

Larimar Therapeutics announced the submission of the first module of its Biologics License Application for nomlabofusp and positive long-term data from its open-label study in Friedreich's Ataxia.

Larimar Therapeutics held its 2026 Annual Meeting of Stockholders, with key proposals including director elections, executive compensation, and an increase in authorized shares receiving majority approval.

Larimar Therapeutics announced Q1 2026 financial results and operational highlights, including plans to initiate a rolling BLA submission for nomlabofusp in June 2026, with $200.4 million in cash providing runway into Q2 2027.

Larimar Therapeutics announced its Q4 and full-year 2025 financial results, highlighted by Breakthrough Therapy Designation for nomlabofusp and a strengthened balance sheet.

Larimar Therapeutics, Inc. announced the pricing of a public offering of 23 million shares of common stock at $5.00 per share, expecting net proceeds of approximately $107.6 million.

Larimar Therapeutics announced FDA Breakthrough Therapy Designation for nomlabofusp in Friedreich's ataxia, targeting a June 2026 BLA submission.

Larimar Therapeutics exchanged 2.5 million common shares for 250,000 Series A convertible preferred shares with a key investor, increasing authorized preferred stock to 500,000.

Larimar Therapeutics reports $136.9 million in cash and targets a Q2 2026 BLA submission for nomlabofusp, aiming for an early 2027 U.S. launch for Friedreich's Ataxia.

Larimar Therapeutics exchanged 2.5 million common shares for 250,000 Series A convertible preferred shares with Blue Owl Healthcare Opportunities IV Public Investments LP.

Larimar Therapeutics provides positive clinical data for nomlabofusp, targeting a Q2 2026 BLA submission for Friedreich's Ataxia.

Larimar Therapeutics announced third quarter 2025 financial results and positive long-term clinical data for nomlabofusp in Friedreich's ataxia, targeting a BLA submission in Q2 2026.

Larimar Therapeutics reports positive long-term data for nomlabofusp in Friedreich's Ataxia, maintaining its Q2 2026 BLA submission target for accelerated approval.

Larimar Therapeutics announced positive long-term open label study data for nomlabofusp in Friedreich's ataxia, showing increased frataxin levels and clinical improvements, alongside a modified dosing regimen and a Q2 2026 BLA target.

Larimar Therapeutics reported Q2 2025 financial results and provided key updates on its nomlabofusp program for Friedreich's ataxia, including a strengthened cash position and clear regulatory path.

Larimar Therapeutics, Inc. has entered into an underwriting agreement to sell 21,562,500 shares of common stock at $3.20 per share, expecting net proceeds of approximately $64.4 million to fund its operations.

Larimar Therapeutics, Inc. announced a preliminary cash, cash equivalents, and marketable securities balance of approximately $138.5 million as of June 30, 2025, disclosed in a prospectus supplement.

Larimar Therapeutics, Inc. announced an updated corporate presentation detailing significant progress for its Friedreich's ataxia drug nomlabofusp, including clear FDA guidance for accelerated approval and positive long-term clinical data.

Larimar Therapeutics announced refined timelines for its nomlabofusp Biologics License Application submission for Friedreich's Ataxia to incorporate FDA-recommended safety data, now targeting Q2 2026 for accelerated approval.

Larimar Therapeutics held its 2025 Annual Meeting of Stockholders, with shareholders voting on the election of a Class II director, executive compensation, and the ratification of the company's independent auditor.

Larimar Therapeutics is advancing its nomlabofusp program for Friedreich's ataxia, targeting a BLA submission by year-end 2025 and potential accelerated approval based on skin FXN concentrations.

Larimar Therapeutics announced its Q1 2025 financial results, highlighting progress in its nomlabofusp clinical development program and plans for a BLA submission by year-end 2025.

Larimar Therapeutics reports progress on its nomlabofusp program for Friedreich's ataxia, including positive FDA feedback on a potential accelerated approval pathway and a BLA submission targeted for year-end 2025.

Larimar Therapeutics awards performance-based restricted stock units (PSUs) to its executive officers, contingent upon achieving regulatory milestones.

Larimar Therapeutics is advancing its lead candidate, nomlabofusp, for Friedreich's ataxia, with positive data from ongoing studies and plans for a BLA submission in the second half of 2025.

Larimar Therapeutics reported positive initial data from its long-term open label extension study of nomlabofusp, showing increased frataxin levels and early trends of clinical improvement in patients with Friedreich's ataxia.

Larimar Therapeutics presented a corporate update highlighting the progress of their lead candidate, nomlabofusp, for the treatment of Friedreich's ataxia, including clinical trial results and future development plans.

Larimar Therapeutics reported its third quarter 2024 financial results and provided an update on the development of its lead drug candidate, nomlabofusp, for Friedreich's ataxia.

Larimar Therapeutics announced its second quarter 2024 financial results and provided updates on its nomlabofusp clinical program, including participation in the FDA's START pilot program.

Larimar Therapeutics is progressing its lead candidate, nomlabofusp, for Friedreich's ataxia, with positive clinical trial results and participation in the FDA's START pilot program.